Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features

被引：18

作者：

Alamy, SS

Jarskog, LF

Sheitman, BB

Lieberman, JA

机构：

[1] Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC 27599 USA

[2] Univ N Carolina, Sch Med, UNC Schizophrenia Res Ctr, Chapel Hill, NC 27599 USA

[3] Dorothea Dix Hosp, Raleigh, NC USA

来源：

SCHIZOPHRENIA RESEARCH | 2004年 / 66卷 / 2-3期

关键词：

secretin; schizophrenia; autism; treatment-resistant; neurodevelopment;

D O I：

10.1016/j.schres.2003.07.003

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Secretin, a gastrointestinal (GI) peptide, may offer therapeutic benefit in autism. Autistic features can also be present in schizophrenia and a recent study suggested a role for adjunctive secretin in treatment-resistant schizophrenia. The current report describes one patient with undifferentiated schizophrenia and prominent autistic features who received a single dose of secretin and demonstrated substantial yet transient improvement. The case illustrates the potential role of secretin as a novel adjunctive treatment strategy in schizophrenic patients with autistic features. (C) 2003 Elsevier B.V. All rights reserved.

引用

页码：183 / 186

页数：4

共 24 条

[1] GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder [J].